Real time-PCR assays. The vitamin C and NO assays were performed as previously described 1 . Briefly, Mtb grown in tissue culture flasks, laying flat to promote an aerated environment, were seeded at an OD 600 of 0.6 were pretreated with 80 µM HC104A, HC106A or a DMSO control for 24 h, and induced with 50 µM DETA-NONOate or 20 mM vitamin C for 2 h.
with washing buffer (20 mM Tris-HCl, pH 8.0, 10% glycerol, 500 mM NaCl) without imidazole, then with 20 mM imidazole. The protein was eluted with the same buffer containing 300 mM imidazole. The fractions with the most DosR protein (as determined by SDS-PAGE) were pooled together for dialysis in 25 mM Tris-HCl, pH 8.0. The final protein concentration was determined using a Qubit kit (Invitrogen).
Electrophoretic mobility assay. The assay is fluorescence-based using 6-carboxyfluorescein (6FAM) labeled 385 bp probe from the hspX promoter. In designing the primer set, 6FAM was added to the 5' ends of forward and reverse primers. The hspX probe was synthesized via PCR using the primer set: forward primer 5'-6FAM-CAACTGCACCGCGCTCTTGATG-3'; reverse primer 5'-6FAM-CATCTCGTCTTCCAGCCGCATCAAC-3'. The probe was purified by Qiagen PCR purification kit. The DosR protein was pre-phosphorylated in 10 µL of phosphorylation buffer (40 mM Tris-HCl, pH 8.0, 5 mM MgCl 2 , 50 mM lithium potassium acetyl phosphate), and incubated at room temperature for 30 min. The protein was then transferred to binding buffer in a final volume of 20 µL (final concentration, 25 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 20 mM KCl, 6 mM MgCl 2 , 10 nM probe, 1 µg poly-dI-dC (Sigma Aldrich)), and treated with HC104A or an equal volume of DMSO or virstatin (Santa Cruz Biotech). Two different assays were performed.
Firstly, different DosR protein concentrations from 0.5 µM to 4 µM were treated with 40 µM.
Second, dose response assays were performed with 2 µM DosR treated with different concentrations of HC104A or virstatin from 1 µM to 80 µM. After incubating on ice for 30 min, the reactions were terminated by adding 1 µL 80% glycerol, and loaded on a native 5% Tris/Borate/EDTA (TBE) polyacrylamide gel. The gel was run at 50 V, for 5-6 h at 4°C in 1X TBE buffer, and was imaged using a Typhoon scanner with appropriate filters that can detect florescence at excitation = 495 nm, emission = 520 nm. Binding of the unbound probe was quantified using ImageJ 3 . The assay was repeated at least twice with similar results. The error bar represents the s.d. of two biological replicates.
Autophosphorylation assay. The DosS autophosphorylation assay was performed as previously described 1 . Recombinant DosS protein was treated with 10 µM, 20 µM or 40 µM of HC104A, or HC106A. DMSO and 40 µM HC103A were also included as positive and negative controls, respectively.
UV-visible spectroscopy assay.
DosS, DosT and mutant proteins were purified and analyzed as previously described 1 . Briefly, 7.5 µM of recombinant DosS protein was deoxygenated with argon gas in a sealed cuvette. The protein was reduced with 400 µM DTN for 20 min. The reaction was then treated with 100 µM HC106A, 400 µM HC104A, 100 µM CORM-2 (tricarbonyldichlororuthenium (II) dimer) or equal volume of DMSO. The UV-visible spectra were recorded for kinetic changes over 2 h. The experiment was repeated at least twice with similar results. DosT was deoxygenated in a hypoxia chamber and treated examined as described for DosS using HC106A.
Kinetic solubility assay. The assay was performed with 7-point (2-fold) dilutions from 200 μM -3.125 μM for HC106 analogs. Mebendazole, benxarotene and aspirin were also included as controls. The drug dilutions were added to PBS, pH 7.4, with the final DMSO concentration of 1%, and incubated at 37 °C for 2 h. The absorbance at 620 nm was measured for each drug dilution to estimate of the compound solubility. Three replicates were examined for each dilution.
Checkerboard synergy studies. The reporter strain CDC1551 (hspX::GFP) was treated with pairs of DosRST inhibitors from 50 µM -0.08 µM in 96-well plates, including HC101A-HC104A and HC106A. GFP fluorescence and OD 600 were measured after 6 d incubation. The percentage of fluorescence inhibition (FI) and growth inhibition were calculated for each drug pair, with limited growth inhibition observed. The FI data was utilized for further analysis of interactions using CompuSyn software 6 . The Combination Index (CI) value was calculated for each drug pair according to the Chou-Talalay method, which is based on the Median-Effect equation derived from the Mass-Action Law principle 7, 8 . The resulting CI values provide quantitative determination of drug interactions, including synergism (CI < 1), additive effect (C = 1), and antagonism (C > 1).
Sources of commercial compounds. HC104A was purchased from Asinex, HC106A was purchased from Maybridge, Virstatin was purchased from Cayman Chemicals.
General procedure for urea (4) formation
Formation of 1,2-oxazolidine-5-carbonyl chloride (2) . To a stirred solution of 1.0 eq. of N-(4chlorophenyl)-1,2-oxazole-5-carboxamide (1) in dry tetrahydrofuran (THF, 0.4 M) under N 2 atmosphere was added oxalyl chloride (1.5 eq.) dropwise over 5-10 min followed by 1 drop of dimethylformamide and the reaction mixture was continued to stir at room temperature. Upon completion, the reaction mixture was concentrated into a residue in vacuo and the residue was redissolved in THF and concentrated again (process repeated 3 times) to ensure the removal of excess oxalyl chloride. The crude acyl chloride 2 was used directly in the next step without further purification. 1 1 1 {[1,1'-biphenyl]-4-yl}-3-(1,2-oxazol-5-yl)urea (MSU-41443) . 1 1 1 1 3-(2-methylpropyl)-1-(1,2-oxazol-5-yl)urea (MSU-41542) . 1 
1-(6-chloropyridin-3-yl)-3-(1,2-oxazol-5-yl)urea (MSU-39448).

3-(5-chloropyridin-2-yl)-1-(4-methylphenyl)urea (MSU-41324).
1,3-bis(4-chlorophenyl)urea (MSU-41425)
1-
1-(4-tert-butylphenyl)-3-(1,2-oxazol-5-yl)urea (MSU-41442).
1-(4-bromophenyl)-3-(1,2-oxazol-5-yl)urea (MSU-41464).
1-(3-bromophenyl)-3-(1,2-oxazol-5-yl)urea (MSU-42003).
(2-(4-chlorophenyl)-N-(1,2-oxazol-5-yl)acetamide (MSU-39449).
A slurry of 4-chlorophenyl acetic acid (0.10 g, 0.60 mmoles) in 2.0 mL of dichloromethane was treated with oxalyl chloride (0.12 mL, 0.9 mmoles) and 1 drop of dimethylformamide. The mixture (with gas evolution) gradually became homogeneous and was stirred for 30 min. The mixture was concentrated in vacuo, diluted with 5 mL of dichloromethane and again concentrated in vacuo, the process repeated three times. The resulting residue was again dissolved in dichloromethane (2 mL) and treated with 5-aminoisoxazole (0.030 g., 0.36 mmoles), followed by pyridine (0.48 mL, 0.6 mmoles). The mixture was then allowed to stir overnight. The mixture was then quenched with 1.0 N HCl and extracted with dichloromethane. The organic layers were combined, washed with saturated KHCO 3 , dried with Na 2 SO 4 and concentrated in vacuo. Medium pressure liquid chromatography (SiO 2 , 100% dichlormethane to 3% methanol / dichloromethane) to provide a solid (0.023 g). 1 
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